	US 11,884,927 B2
	Fusion constructs as protein over-expression vectors
Anastasios Melis, El Cerrito, CA (US); and Cinzia Formighieri, Berkeley, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Dec. 11, 2020, as Appl. No. 17/119,670.
Application 17/119,670 is a division of application No. 15/739,101, granted, now 10,876,124, previously published as PCT/US2016/039050, filed on Jun. 23, 2016.
Claims priority of provisional application 62/185,181, filed on Jun. 26, 2015.
Prior Publication US 2021/0139921 A1, May 13, 2021
Int. Cl. C12N 15/74 (2006.01); C12N 9/88 (2006.01); C12Q 1/68 (2018.01); G01N 33/569 (2006.01)

CPC C12N 15/74 (2013.01) [C12N 9/88 (2013.01); C12Y 402/0302 (2013.01); C12Y 402/03051 (2013.01); C07K 2319/02 (2013.01)]

24 Claims

1. An expression construct comprising a polynucleotide encoding a fusion protein, said fusion protein comprising a protein of interest to be expressed in cyanobacteria joined to a bacterial neomycin phosphotransferase protein that confers resistance to kanamycin or a chloramphenicol acetyl transferase protein that confers resistance to chloramphenicol;

wherein the polynucleotide comprises a transgene encoding the protein of interest that is codon-optimized for expression in cyanobacteria and is joined to the 3′ end of a nucleic acid encoding the bacterial neomycin phosphotransferase (NPT) protein or the chloramphenicol acetyltransferase protein.